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 Abstract
Aim: The aim of the study was to evaluate IL-10 and TGF-beta levels in the peritoneal fluid (PF) and plasma of 
patients with ovarian cancer (n=104), serous cyst (n=32) or normal controls (n=20). IL-10 and TGF-beta levels were 
correlated to myeloid (M) and lymphoid (L) dendritic cells (DC). 
Material and Methods: IL-10 and TGF-beta concentrations were evaluated using the enzyme linked immunosorbent 
assay (ELISA). The percentage of DC in mononuclear cells was quantified by using flow cytometry. 
Results: The PF and plasma IL-10 concentrations were significantly higher in epithelial ovarian cancer (EOC) 
patients when compared to the women with serous cyst (the reference group). Plasma levels of IL-10 were elevated 
in EOC patients in comparison with the reference and control groups. There were significant differences in the PF 
and plasma IL-10 levels with respect to tumor stage, grade and histology. Significant negative correlations were 
found between the plasma IL-10 levels, MDC and LDC in the peripheral blood.
TGF-beta levels were detected in PF of all EOC patients and were significantly lower when compared with plasma. 
Plasma levels of TGF-beta were elevated in EOC patients compared with the control group. No significant differences 
in the PF and plasma TGF-beta levels were noted between EOC patients and the reference group. The authors did 
not find a correlation between the plasma and PF TGF-beta levels and the percentage of MDC and LDC.
Conclusions: IL-10 production in EOC patients depends on the tumor stage, grade and histological type of the 
tumor cells. IL-10 may have impact on the percentage of dendritic cells in EOC patients. 
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Introduction
Despite	 advancements	 in	 chemotherapy	 and	 surgical	
technique,	morbidity	and	mortality	 rates	 for	ovarian	cancer	are	
still	very	high	[1].	It	is	well	known	that	cancer	cells	develop	many	
mechanisms	which	impede	their	identification	and	destruction	by	
the	 immune	 system	 [2].	One	 such	mechanism	 is	production	of	
factors	modifying	the	function	of	antigen-	presenting	cells	(APC).	
The	 fact	 that	 ovarian	 cancer	 cells	 produce	 immunosuppressive	
cytokines	 like	 	 IL-10	[3,	4],	TGF-β	[5,	6],	vascular	endothelial	
growth	factor	 (VEGF)	[7]	or	proinflammatory	cytokines	(IL-6)	
[8],	which	inhibit	or	decrease	maturation	and	activation	of		APC	
[2]	 had	 been	 reported	 in	 literature.	 Progression	 of	 malignant	
tumors	decreases	the	number	of	dendritic	cells	(DC),	which	are	
the	most	potent	among	antigen-presenting	cells	[9,	10].	The	latest	
published	 data	 reported	 a	 significant	 role	 of	 IL-10	 and	TGF-β	
in	 the	 differentiation,	 maturation	 and	 function	 of	 DC	 [11,12].	
In vitro,	 IL-10	 /TGF-β	 -	 treated	 DC,	 (10/TGF-DC),	 revealed	
decreased	expression	of	costimulatory	molecules,	class	II	major	
histocompatibility	complex	antigens	(HLA-DR)	and	maturation	
markers	 (CD83)	 [13].	 Furthermore,	 10/TGF-DC	 induced	
tolerance	in	memory	T-cells	and	the	differentiation	of	regulatory	
T-cells	(Tregs)	[11].
Aim of the study
The	 aim	 of	 the	 study	 was	 to	 estimate	 IL-10	 and	 TGF-β	
levels	in	the	plasma	and	peritoneal	fluid	(PF)	of	ovarian	cancer	
patients.	In	addition,	the	study	aimed	to	evaluate	the	correlation	
between	the	IL-10	and	TGF-β	concentrations	and	the	percentage	
of	myeloid	and	lymphoid	DC.	In	ovarian	cancer	patients,	plasma	
and	 PF	 cytokine	 concentrations	 were	 analyzed	 in	 relation	 to	
International	 Federation	 of	 Gynecologists	 and	 Obstetricians	
(FIGO)	stage,	histopathological	grade	and	type	of	the	tumor.
Materials and methods
The	study	analyzed	104	ovarian	cancer	patients	(median	age	
56	years;	min.	22,	max.	85	years),	who	had	undergone	laparotomy	
between	2004-2010	in	the	I	Chair	and	Department	of	Oncological	
Gynaecology	and	Gynaecology,	Medical	University	of	Lublin.	
Peripheral	 blood	 (PB)	 and	 peritoneal	 fluid	 were	 collected	
for	the	study.	The	reference	group	consisted	of	32	patients	with	
ovarian	serous	cysts	(SC)	(median	age	28	years;	min.	22	–	max.78	
years).	 The	 control	 group	 comprised	 of	 blood	 donors	 in	 good	
health	 condition	 (n=20),	 (median	 age	29	years;	min.	 21–	max.	
51	years).	
Plasma	was	collected	after	immediate	centrifugation	(3.000	
rpm	 for	 10	min.)	 of	 8ml	PB	drawn	 into	 heparinized	 tubes.	 PF	
was	collected	from	peritoneal	cavity	during	surgery.	Centrifuged	
plasma	and	PF	were	stored	at	-80°C	before	being	tested	by	ELISA	
(enzyme-linked	immunosorbent	assay).	
Estimation of  IL-10 and TGF-β concentration in plasma  
and PF 
Concentrations	 of	 IL-10	 and	TGF-β	were	 estimated	 using	
ELISA	assay.	Analysis	was	done	with	available	kits:	human	IL-
10	 (	R$D	System,	USA),	 sensitivity	<3.9	 pg/ml,	 human	TGF-
β1(Bender	MedSystems,	USA),	sensitivity	<9pg/ml,	according	to	
manufacturer’s	protocols.	All	samples	were	assayed	in	duplicate.
MDC	 and	 LDC	 were	 estimated	 by	 flow	 cytometry	 with	
the	use	of	monoclonal	antibodies:	anti-BDCA-1	 (CD1c)	FITC,	
anti-BDCA-2	 (CD303)	 FITC	 (Miltenyi	 Biotec,	 Bergisch	
Gladbach,	 Germany)	 and	 anti-CD19	 Cy-Chrome,	 anti-CD123	
PE	 (Pharmingen,	 San	Diego,	California,	USA).	Details	 on	 the	
method	of	DC	isolation	and	identification	were	published	in	our	
earlier	work,	Wertel	et.	al.,	2008	[14].	Results	were	presented	as	a	
percentage	of	MDC	and	LDC	in	mononuclear	cells	(PBMC).
Statistical analysis
Results	 were	 analyzed	 using	 Statistica	 9.0.	 software	 and	
nonparametric	 tests.	 The	 Wilcoxon	 paired	 test	 was	 used	 to	
compare	 results	 in	 the	 PF	 and	 plasma.	 The	Mann-Whitney	 U	
test	was	used	 to	 compare	 the	 studied	groups.	Spearman’s	 rank	
test	was	used	to	assess	the	relationship	between	cytokines	levels	
and	DC.	 P	 value	 of	 less	 than	 0.05	was	 considered	 statistically	
significant.	Data	were	presented	as	medians	and	range.
 Streszczenie
Cel: Ocena stężenia interleukiny (IL)-10 i transformującego czynnika wzrostu beta (TGF-β) w osoczu i płynie 
otrzewnowym (PO) chorych na raka jajnika oraz ustalenie czy istnieje zależność pomiędzy ich stężeniem a 
odsetkiem mieloidalnych (M) i limfoidalnych (L) komórek dendrytycznych (DC).
Materiał i metody: Stężenie IL-10 i TGF-β oceniono u chorych na raka jajnika (n=104), z torbielą surowiczą jajnika 
(grupa referencyjna , n=32) oraz w grupie kontrolnej (n=20) metodą immunoenzymatyczną ELISA. Odsetek MDC 
i LDC oceniano metodą cytometrii przepływowej. 
Wyniki: Stężenie IL-10 w PO chorych na raka jajnika było istotnie wyższe niż w grupie referencyjnej. Ponadto stężenie 
IL-10 w osoczu chorych na raka jajnika było wyższe niż w grupie referencyjnej i kontrolnej. Odnotowano istotne 
statystycznie różnice stężeń IL-10 w osoczu i PO chorych na raka jajnika w zależności od stopnia zaawansowania 
nowotworu wg FIGO, stopnia zróżnicowania histologicznego oraz typu histologicznego nowotworu.
Stężenie IL-10 w osoczu chorych na raka jajnika istotnie ujemnie korelowało z odsetkiem MDC oraz LDC krwi 
obwodowej.
Stężenie TGF-β w osoczu i PO chorych na raka jajnika nie różniło się istotnie od odnotowanego w grupie 
referencyjnej. Stężenie TGF-β w osoczu chorych na raka jajnika jak i grupie referencyjnej było wyższe niż w grupie 
kontrolnej. Nie wykazano istotnej korelacji pomiędzy stężeniem TGF-β w osoczu i PO a odsetkiem MDC i LDC 
u chorych na raka jajnika.
Wnioski: Zaobserwowana w badaniach istotna ujemna korelacja pomiędzy stężeniem IL-10 w osoczu 
chorych na raka jajnika a MDC oraz LDC krwi obwodowej może sugerować wpływ IL-10 na odsetek komórek 
dendrytycznych. 
 Słowa kluczowe: komórki dendrytyczne / rak jajnika / IL-10 / TGF-beta / 
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Results
Estimation of IL-10 in ovarian cancer, serous cyst (SC)  
and healthy women
Results	 are	 presented	 in	 Table	 I.	 Concentration	 of	 IL-10	
in	 the	 PF	 of	 ovarian	 cancer	 patients	 and	 in	 the	 SC	 group	was	
significantly	 higher	 (p<0.001)	 than	 in	 plasma.	 Furthermore,	
plasma	IL-10	levels	in	ovarian	cancer	group	was	higher	(p<0.001)	
than	in	the	reference	and	control	group.	No	significant	difference	
was	found	in	the	plasma	IL-10	levels	between	the	reference	and	
control	 group.	 (Figure	 1a).	 PF	 IL-10	 concentration	 in	 ovarian	
cancer	 patients	 was	 higher	 (p<0.001)	 than	 estimated	 in	 the	
reference	group.	(Figure1b).
Significant	 differences	 in	 the	 ovarian	 cancer	 group	 were	
found	in	the	plasma	and	PF	IL-10	concentration	in	correlation	to	
FIGO	stage,	histopathological	grade	and	type	of	tumor.	Results	
are	presented	in	Table	I.
Estimation of TGF-β in ovarian cancer, serous cyst (SC)  
and healthy women
Results	 are	 shown	 in	 Table	 II.	 The	 plasma	 TGF-β	 levels	
in	 ovarian	 cancer	 and	 SC	 patients	 were	 significantly	 higher	
(p<0.001)	than	estimated	in	PF.	In	the	ovarian	cancer	and	the	SC	
group,	the	plasma	TGF-β	concentration	was	significantly	higher	
(p<0.001)	than	in	the	control	group.	No	significant	difference	was	
found	in	the	plasma	TGF-β	level	between	the	ovarian	cancer	and	
the	reference	group	(p=0.09).	(Figure	2a).	Peritoneal	fluid	TGF-β	
concentration	 estimated	 in	 ovarian	 cancer	 patients	 and	 in	 the	
reference	group	presented	the	same	level.	(Figure	2b).
TGF-β	 concentration	 in	 the	 PF	 of	 patients	 with	 FIGO	 III	
stage	of	ovarian	cancer	was	higher	than	in	I,	II	and	IV	stage	of	
tumor,	but	the	difference	was	not	statistically	significant.	
Estimation	 of	 TGF-β	 concentration	 in	 correlation	 to	
histopathological	 type	of	 tumor	did	not	 reveal	 any	differences.	
(Table	II).	The	concentration	of	plasma	TGF-β	was	higher	in	the	
endometrioid	than	serous	type	of	tumor.	(Table	II).
Estimation of MDC and LDC percentage in the PF and PB 
of patients  with ovarian cancer, serous cyst (SC) and healthy 
women
MDC	and	LDC	were	found	in	the	peripheral	blood	and	PF	of	
all	studied	patients.	Results	are	presented	in	Figure	3,	4.
Correlation between the plasma and PF IL-10 and TGF-β 
concentration and percentage of MDC and  LDC in ovarian 
cancer patients 
The	 plasma	 IL-10	 concentration	 revealed	 significant	
negative	 correlation	with	percentage	of	 peripheral	 blood	MDC	
(	 R=-0.20,	 t(N-2)	 =-1.94,	 p=0.05)	 and	 LDC	 (	 R=-0.23,	 t(N-2)	
=-2.26,	p=0.02).	Furthermore,	a	positive	correlation	between	PF	
IL-10	concentration	and	lymphoid	DC	percentage	(R=0.17,	t(N-
2)=1.79,	p=0.07)	was	found.	
No	significant	correlation	was	found	between	the	plasma	IL-
10	levels	and	percentage	of	MDC	in	PF.
No	significant	correlation	was	found	between	the	plasma	and	
peritoneal	fluid	TGF-β	concentration	and		percentages	of	MDC	
and	LDC	in	ovarian	cancer	patients.	
Discussion
Cytokines,	like	IL-	10,	IL-	6,	TGF-β	and	VEGF,	present	in	
the	 cancerous	 microenvironment	 affect	 the	 antigen-presenting	
cells	 status	 [2,	 15].	 Supernatants	 obtained	 from	 the	 cancerous	
cell	 cultures	 have	 an	 adverse	 effect	 on	 differentiation	 of	 DC	
Table I. Levels of IL-10 (pg/ml) in the plasma and PF of patients with ovarian cancer. 
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from	CD34+ or	CD14+ 	 precursors,	 and	 decrease	 expression	 of	
costimulatory	molecules	on	their	surface	[16,	17].	
The	aim	of	our	studies	was	to	evaluate	the	concentrations	of	
selected	immunosuppressive	cytokines	as	IL-10	and	TGF-β	in	the	
plasma	and	peritoneal	fluid	obtained	from	women	with	ovarian	
cancer,	 as	 well	 as	 to	 establish	 whether	 there	 exists	 a	 relation	
between	 their	 concentration	and	 the	percentage	of	professional	
antigen-presenting	cells,	DC	myeloid	and	lymphoid.
Our	studies	showed	that	both	the	PF	and	the	plasma	IL-10	
levels	in	women	suffering	from	ovarian	cancer	were	significantly	
higher	 than	 those	 in	 patients	with	 benign	 ovarian	 cysts.	These	
observations	are	supported	by	results	of	Santin	et	al.	[18],	who	
found	higher	 levels	 of	 IL-10	 in	 the	 peritoneal	fluid	 of	 patients	
with	ovarian	cancer	in	comparison	to	the	plasma	levels.	Zou	et	
al.	[3]	observed	higher	concentrations	of	IL-10	in	the	serum	and	
peritoneal	fluid	of	women	suffering	from	ovarian	cancer	compared	
to	both	healthy	subjects	and	patients	with	benign	ovarian	tumors.	
They	also	found	higher	concentrations	of	IL-10	in	the	peritoneal	
fluid	than	in	serum.	Additionally,	the	peritoneal	fluid	IL-10	levels	
were	significantly	higher	in	women	with	III/IV	FIGO	stages	than	
in	 patients	with	 the	 stage	 II	 of	 the	 disease.	Unlike	 our	 results,	
the	 authors	 did	 not	 notice	 any	differences	 in	 the	 concentration	
of	IL-10	depending	on	the	histological	degree	of	the	cancer	[3].	
Mustea	 et	 al.	 [19]	 also	 observed	 higher	 peritoneal	 fluid	 IL-10	
 
Figure 1ab. 
Table II. Levels of TGF-β (ng/ml) in the plasma and PF of patients with ovarian cancer. 
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Figure 3abcd.  
 
Figure 2ab.  
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levels	 compared	 to	 serum	of	both	patients	with	ovarian	cancer	
and	 women	 with	 benign	 ovarian	 cysts.	 Concentrations	 of	 IL-
10	correlated	with	 the	histological	 type	and	with	 the	degree	of	
differentiation	of	cancer.	In	the	presented	work	we	found	higher	
plasma	 IL-10	 concentrations	 in	 women	 with	 undifferentiated	
cancer	 when	 compared	 to	 mucinous,	 endometrioid,	 clear-cell	
and	endometrioid	or	clear	cell	carcinoma.	Like	Mustea	et	al.	[19],	
we	observed	a	relationship	between	IL-	10	levels	and	histological	
degree	of	the	cancer.	(Table	I).	
Moreover,	 concentrations	of	 IL-	10,	both	 in	 the	plasma	as	
well	as	in	the	peritoneal	fluid,	correlated	with	the	FIGO	stages	of	
ovarian	cancer	classification.	(Table	I).
Higher	 PF	 than	 plasma	 IL-10	 levels	 in	 patients	 with	
ovarian	 cancer	 support	 the	 hypothesis	 of	 the	 local	 IL-10	
production.	 However,	 numerous	 studies	 showed	 that	 not	 only	
cancerous	cells	[3,	4]	but	also	macrophages,	ovarian	carcinoma	
infiltrating	lymphocytes	[18],	dendritic	cells	[20]	and	regulatory	
T-lymphocytes	 (Tregs)	 [21]	 may	 be	 the	 source	 of	 IL-10.	
Consequently,	it	 is	difficult	to	determine	the	source	of	IL-10	in	
women	suffering	from	ovarian	cancer.
Many	studies	showed	that	IL-	10	influences	the	differentiation,	
maturation	 and	 DC	 functions	 in vitro.	 Allavena	 et	 al.	 [22]	
demonstrated	 that	 IL-10	 inhibits	monocytes	differentiation	 into	
DC	 and	 promotes	 the	 development	 of	macrophages-phenotype	
cells.	Other	investigators	[20,	23]	found	that	monocytes	incubate	
with	 IL-10,	 differentiate	 to	 the	 new	 population	 of	 dendritic	
cells,	DC-10,	which	produce	high	amounts	of	IL-10,	but	do	not	
produce	IL-12.	Moreover,	these	cells	stimulate	differentiation	of	
regulatory	lymphocytes	(Tr1) in vitro,	which	by	producing	IL-10	
and	TGF-β,	inhibit	immune	response	[12,	24].
A	 statistically	 significant	 relationship	 between	 plasma	 IL-
10	 concentrations	 in	 women	 suffering	 from	 ovarian	 cancer	
and	peripheral	 blood	MDC	and	LDC	percentages,	 observed	 in	
our	study,	suggests	 the	 influence	of	IL-10	on	the	percentage	of	
dendritic	cells.	 Interestingly	enough,	 the	highest	concentrations	
of	IL-10	and	the	highest	percentage	of	lymphoid	DC	(0.92%	and	
 
Figure 4abcd.  
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0.97%)	were	found	 in	 the	PF	of	women	with	FIGO	III	and	IV	
ovarian	 cancer	 stages.	 Moreover,	 higher	 IL-10	 levels,	 as	 well	
as	 significantly	 higher	LDC	percentage	were	 found	 in	 patients	
with	G3	ovarian	cancers	comparing	to		patients	with	G2	degree	
(1.02%	and	0.47%).
In	 2004	 Curiel	 et	 al.	 [25]	 demonstrated	 the	 accumulation	
of	lymphoid	DC	in	the	peritoneal	fluid	of	patients	with	ovarian	
cancer.	These	cells	produced	high	concentrations	of	angiogenic	
cytokines	 like	 TNFα	 and	 IL-8,	 and	 inhibited	 the	 development	
of	 the	 immune	 response.	 High	 concentrations	 of	 IL-10	 and	
increased	percentage	of	lymphoid	DC	in	the	PF	of	women	with	
advanced	ovarian	cancer,	as	reported	by	our	study,	may	affect	the	
development	of	the	immune	response.
TGF-β,	 which	 suppresses	 DC	 maturation	 and	 stimulates	
their	differentiation	into	cells	which	promotes	the	immunologic	
tolerance,	 is	 the	second	immunosuppressive	cytokine	estimated	
in	our	 study	 [26,	27].	Apart	 from	 the	 influence	on	DC,	TGF-β	
inhibits	the	proliferation	of	T-lymphocytes,	synthesis	of	antibodies	
through	B	lymphocytes,	and	suppresses	cytotoxic	activity	of	NK	
cells	[18].	TGF-β	also	plays	an	important	role	in	differentiation	
of	Tregs	[21].
Similarly	 to	 our	 results,	 Santin	 et	 al.	 [18]	 and	Chen	 et	 al.	
reported	significantly	higher	plasma	TGF-β	levels	in	comparison	
to	PF	concentrations,	 in	patients	 suffering	 from	ovarian	cancer	
[28].	Like	Chen	et	al.	we	did	not	observe	significant	differences	
in	the	plasma	and	peritoneal	fluid	TGF-β	concentration	between	
women	with	ovarian	 cancer	 and	 the	 reference	group	 [27].	Our	
results	 seem	 to	 support	 the	 hypothesis	 of	 Santin	 et	 al.,	 which	
suggests	that	the	source	of	TGF-β	in	patients	with	ovarian	cancer	
comprises	of	mononuclear	cells	rather,	than	cancerous	cells	[18].
Interestingly	enough,	it	can	be	noted	that	the	highest	TGF-β	
concentrations,	 as	 well	 as	 the	 highest	 percentage	 of	 lymphoid	
DC	(0.92%),	were	found	in	women	with	FIGO	III	stage	of	 the	
disease.	In	addition,	LDC	percentages	and	TGF-β	concentrations	
were	 higher	 in	 G3	 ovarian	 cancer	 as	 compared	 to	 G2	 degree	
(1.02%	 and	 0.47%,	 respectively).	 However,	 the	 differences	 in	
TGF-β	concentrations	were	not	statistically	significant.
Conclusions
1.		The	plasma	and	peritoneal	fluid	IL-10	 levels	are	higher	
in	women	with	ovarian	cancer	in	comparison	to	patients	
with	 	 serous	 cysts.	Concentrations	of	 IL-	 10	 in	women	
suffering	from	ovarian	cancer	and	in	the	group	of	patients	
with	the	serous	ovarian	cysts	were	significantly	higher	in	
the	peritoneal	fluid	than	in	plasma.	
2.		Both,	 the	plasma	and	peritoneal	fluid	TGF-β	levels,	did	
not	 differ	 significantly	 between	 patients	 with	 ovarian	
cancer	and	those	with	the	serous	ovarian	cysts.
3.		A	statistically	significant	negative	correlation	was	found	
between	the	concentration	of	IL-	10	in	the	plasma	and	the	
peripheral	blood	MDC	and	LDC	percentages	in	women	
with	ovarian	cancer.
The study was supported by the Polish Ministry of Science 
and Higher Education Grants NN 114036 and NN 160940.
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